Crystal structure of edoxaban tosylate monohydrate Form I, (C 24 H 31 ClN 7 O 4 S)(C 7 H 7 O 3 S)(H 2 O)
Source abstract
Abstract
The crystal structure of edoxaban tosylate monohydrate has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Edoxaban tosylate monohydrate crystallizes in space group P 2 1 (#4) with a = 7.55097(2), b = 7.09010(2), c = 32.80420(21) Å, β = 96.6720(3)°, V = 1744.348(6) Å 3 , and Z = 2. The crystal structure consists of alternating layers of edoxaban cations and tosylate anions along the c -axis. The water molecules lie near the sulfonate end of the tosylate anions. The solid-state conformation of the edoxaban cation is determined by intermolecular interactions. The protonated nitrogen atom forms a strong N–H⋯O hydrogen bond to one of the tosylate oxygens. Only one of the water molecule hydrogens acts as a donor in an O–H⋯O hydrogen bond. The tosylate oxygens act as acceptors in a number of C–H⋯O hydrogen bonds. The powder pattern has been submitted to ICDD ® for inclusion in the Powder Diffraction File™.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Chemical Synthesis and Characterization · Pigment Synthesis and Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. MDI (2020). JADE Pro version 7.8 (Computer software), Materials Data, Livermore, CA, USA.
2. 10.1021/ci049780b10.1021/ci049780b ↗
3. Kawanami, K. and Kitani, Y. (2017). “High-purity crystals of active blood coagulation factor X (FXA) inhibitor,” US Patent Application 2017/0022220 A1.
4. 2013
5. 10.1002/jcc.2315310.1002/jcc.23153 ↗
6. Bravais · 1866
7. Wavefunction, Inc. (2020). Spartan ’18 Version 1.4.0, Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612.
8. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
9. 10.1017/S088571561400090610.1017/S0885715614000906 ↗
10. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
11. Turner · 2017
12. Ohta, T. , Komoriya, S. , Yoshino, T. , Nagamochi, M. , and Ono, M. (2008). “Diamine derivatives,” US Patent 7,365,205 B2.
13. Koyama, T. (2011). “Method for producing diamine derivatives,” European Patent Application EP2371830A1.
14. 2020
15. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
16. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
17. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
18. 10.1002/qua.2465810.1002/qua.24658 ↗
19. Suzuki, T. and Ono, M. (2011). “Crystal of diamine derivative and method of producing same,” Canadian Patent Application CA2793413.
20. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
21. Open babel: an open chemical toolbox
22. 10.1063/1.296926010.1063/1.2969260 ↗
23. 10.1063/1.46788210.1063/1.467882 ↗
24. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
25. Berenguer Maimó, R. , Racamonde Villanueva, M. , and Winter, S. B. D. (2018). “Preparation process of edoxaban tosylate monohydrate,” European Patent Application EP3318568.
26. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
27. 10.1017/S088571561900051410.1017/S0885715619000514 ↗
28. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
29. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
30. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
31. Ohta, T. , Komoriya, S. , Yoshino, T. , Uoto, K. , Nakamoto, Y. , Naito, H. , Mochizuki, A. , Nagata, T. , Kanno, H. , Haginoya, N. , Yoshikawa, K. , Nagamochi, M. , Kobayashi, S. , and Ono, M. (2004). “Diamine derivatives,” European Patent Application EP1405852A1.
32. 10.1107/S002188980604211710.1107/S0021889806042117 ↗
33. 10.1007/BF0054909610.1007/BF00549096 ↗
34. Etudes sur la loi de bravais
35. A new law of crystal morphology extending the law of bravais